Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Souvenaid

- PMLiVE

Brexit – a tough pill to swallow

What will be expected of the UK when the post-Brexit environment takes shape?

Biogen Idec building

Biogen proffers new data to support high-priced Spinraza

Trial demonstrates statistically-significant risk reduction in paediatric SMA for potential blockbuster drug

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

Healthcare comms network GLOBALHealthPR expands into Asia

Newly-launched Asia-Pacific headquarters will be led by James Yi

- PMLiVE

Albumedix appoints Dr Giles Campion as CMO

He brings experience from Novartis and BioMarin

Novo signs personalised digital health deal in diabetes

Will work with Glooko on jointly-developed and branded solutions

- PMLiVE

GPI appoints commercial director

Alan Stewart joins the life science management consultancy's executive team

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

- PMLiVE

Merck pays Vertex $230m upfront for cancer programmes

Licences four DNA damage and repair programmes with first-in-class or best-in-class potential

- PMLiVE

NICE U-turn on Novartis’ Afinitor for kidney cancer

Set to back treatment's routine NHS use following offer of discount and new data

Shire Basingstoke

Shire pays record $350m to settle US kickback allegations

Charges centred around diabetic foot ulcer treatment Dermagraft, which it sold in 2014

- PMLiVE

Newron Pharma appoints commercial affairs VP

Dennis Dionne brings expertise from J&J and Novartis

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links